Spinraza Plus Zolgensma Offers Little Extra Benefit in Type 1, Study Suggests

Spinraza Plus Zolgensma Offers Little Extra Benefit in Type 1, Study Suggests

314624

Spinraza Plus Zolgensma Offers Little Extra Benefit in Type 1, Study Suggests

Combined treatment with Spinraza and Zolgensma does not markedly improve motor function or breathing ability in children with spinal muscular atrophy (SMA) type 1, a small, single-site study reported. Its scientists highlighted that, regardless of the type of treatment given, earlier treatment leads to better outcomes. The study, “Combination Therapy with Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type I,” was published in the Journal of Clinical Medicine. Spinraza and Zolgensma both work to increase levels of the…

You must be logged in to read/download the full post.